TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Are able to provide written informed consent Have a confirmed diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual (DSM) 5 criteria using the SCID (Structured Clinical Interview for DSM disorders) Are between the ages of 18 and 35, inclusive Have the following history with antipsychotic medications~1. First episode subjects: \< 1 year of lifetime exposure to antipsychotic medication and only one episode of psychosis~2. EP subjects: between 1 year and 5 years of lifetime exposure to antipsychotic medication or subjects with \< 1 year of lifetime antipsychotic medication and more than one episode of psychosis.~For LAI subjects: Must be willing to accept an injectable form of treatment~Exclusion Criteria:~Have a current primary DSM-5 diagnosis other than schizophrenia, including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, and amnestic or other cognitive disorders.~For LAI sites only - have a known allergy or intolerance to aripiprazole, or a past negative response to aripiprazole that is not explained by nonadherence Be pregnant or lactating Have any unstable medical condition that, in the opinion of the investigator, would be detrimental to the subject or would confound the results of the study Subjects in the MRI subset only- presence of any metal implants, pacemakers, irremovable prosthetic devices, or other devices or situations that may preclude imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Clinician's Choice (Type: ACTIVE_COMPARATOR): Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
- Aripiprazole Once Monthly (Type: EXPERIMENTAL): Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent to participate in the study obtained~* Signed informed consent to participate in the optional pharmacogenomic component of the study obtained (refusal to give consent for the pharmacogenomic component of the study does not exclude a patient from participation in the clinical study)~* Confirmation of diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) within 5 years prior to screening~* Patient is willing and able to fill out self-administered questionnaires during the study~* confirmation that patient has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time before enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication~Exclusion Criteria:~* The patient's psychiatric diagnosis is due to the direct pharmacological effects of a drug of abuse substance or medication, or is due to a general medical condition (eg, clinically notable hypothyroidism)~* The patient is treatment resistant in the judgment of the investigator~* The patient meets the DSM-IV definition of substance dependence (except for nicotine and caffeine) within 6 months prior to entry~* The patient has a previously defined hypersensitivity (anaphylaxis-type reaction) to risperidone or paliperidone or excipients~* The patient has received treatment with a long-acting injectable antipsychotic within 3 injection cycles prior to baseline, received clozapine within 3 months prior to screening, received treatment with other investigational agents within 30 days of the screening visit, has participated in more than one investigational drug study in the past 12 months, or has planned use of other investigational drugs during the time frame of the study~* History or current symptoms of tardive dyskinesia, history of neuroleptic malignant syndrome, or evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone palmitate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of SLE according to the American College of Rheumatology (ACR) criteria~2. Age \>16 years~3. Proteinuria ≥500 mg in 24 hours/ urine routine microscopy showing active cellular casts/sediments.~4. Biopsy-proven proliferative lupus glomerulonephritis of class III, IV according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria.~Exclusion Criteria:~1. Patients ever treated previously with intravenous or oral cyclophosphamide or received steroids \>15mg/day in the last 3 months.~2. Patients with renal thrombotic microangiopathy, preexisting chronic renal failure, pregnancy, previous malignancy (except skin and cervical intraepithelial neoplasia), diabetes mellitus or coronary heart disease.~3. Patients with previously documented severe toxicity to immunosuppressive drugs.~4. Patients with acute/chronic infections.~5. Pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose Cyclophosphamide (Type: ACTIVE_COMPARATOR): Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
- High Dose Cyclophosphamide (Type: ACTIVE_COMPARATOR): Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of active ME secondary to any causes (for adult patients: except diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO));~* BCVA must be between ≥ 24 and ≤ 83 letters;~* Visual loss should be mainly due to the presence of any eligible types of ME.~Exclusion Criteria:~* Women of child-bearing potential,~* Active malignancies;~* History of stroke less than 6 months prior to screening;~* Uncontrolled systemic inflammation or infection, related directly to the underlying causal disease of ME;~* Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;~* Any type of advanced, severe or unstable ocular disease or its reatment;~* ME with a high likelihood of spontaneous resolution.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
- Sham control (Type: SHAM_COMPARATOR): Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents with a diagnosis of ADHD, who also have a child with an ADHD between the ages of 5-16~Exclusion Criteria:~* Parents with any of the following: any identified structural heart abnormality or other health condition that significantly affects heart performance (e.g., hypertension), a resting systolic blood pressure ≥140 and diastolic blood pressure ≥90, pregnant or breast feeding, significant psychiatric problems other than ADHD that currently require medication or any emergent psychiatric treatment, medical/psychiatric illness that could be worsened by stimulants (such as a seizure disorder, Tourette's Disorder or hyperthyroidism), or alcohol or substance abuse problems in the past 6 months.~* Children with any of the following: any psychiatric problem other than ADHD, Oppositional Defiant Disorder (ODD), or Conduct Disorder (CD) that requires medication or any emergent psychiatric treatment, either parent or child has participated in the same parent-child interaction task used in this study in the last 6 months, either as part of a study or a clinical treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- stimulant medication (Type: EXPERIMENTAL): blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
- placebo pill (Type: PLACEBO_COMPARATOR): placebo medication identical in appearance to active med

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All adult subjects over the age of 18 with chronic pain\* presenting to the emergency department with exacerbation of their chronic pain as their primary complaint~* Subjects who are willing and able to provide informed consent. \*Chronic pain defined as greater \> 3 months of symptoms and an initial VAS pain score \> 70~Exclusion Criteria:~* History of overt psychosis, severe hypertension as defined by Systolic Blood Pressure \> 180 mm Hg or Diastolic Blood Pressure \>110 mm Hg, unstable angina, Coronary Artery Disease, Congestive Heart Failure, porphyrias, thyroid disease, seizure disorder, inability to provide informed consent: dementia, non-English/Spanish speakers, subjects in custody, suicidal, or clinically intoxicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo controlled arm
- very low dose ketamine (Type: EXPERIMENTAL): 0.25 mg/kg of sub-dissociative ketamine as an experimental arm
- low dose ketamine (Type: EXPERIMENTAL): 0.50 mg/kg of sub-dissociative ketamine as an experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subject~* Age: 18 to 45 years (inclusive) at the first screening / examination visit~* Ethnicity: Caucasian~* Body mass index (BMI): \>/=18 and \</=29,9 kg/m²~Exclusion Criteria:~* Systolic blood pressure below 120 or above 145 mmHg~* Diastolic blood pressure above 95 mmHg~* Heart rate below 45 or above 95 beats / min~* Clinically relevant findings in the physical examination~* Suspicion of drug or alcohol abuse~* Regular daily consumption of more than 1 L of xanthin-containing beverages~* Intake of foods or beverages containing grapefruit within 4 weeks before the pre-study examination

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Nifedipine-candesartan FDC (Type: EXPERIMENTAL): Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
- Nifedipine and candesartan (Type: ACTIVE_COMPARATOR): Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
- Nifedipine (Type: ACTIVE_COMPARATOR): Each subject received one dose of nifedipine GITS 60 mg orally.
- Candesartan (Type: ACTIVE_COMPARATOR): Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 cases~* Oxygen saturation \> 93%~* Age \>18 years~Exclusion Criteria:~* Patients \<18 years,~* patients with Oxygen saturation \< 93%, patients with~* Diabetes mellitus or~* heart failure,~* patients on chemotherapy or immunosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clarithromycin (Type: EXPERIMENTAL): clarithromycin group
- Azithromycin (Type: ACTIVE_COMPARATOR): azithromycin group
- control (Type: PLACEBO_COMPARATOR): control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus diagnosed for at least 6 months~* Current usage of subcutaneous insulin pump treatment~* Age 18-65 years~* HbA1c of 5.5 - 7.7% at screening visit~* BMI 18-35 kg/m2~* Willingness to follow all study procedures, including attending all clinic visits~* Willingness to sign informed consent and HIPAA documents~Exclusion Criteria:~* Pregnancy or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test.~* Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).~* Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.3 g/dL; or serum bilirubin of over 2.~* Hematocrit of less than or equal to 34%.~* Congestive heart failure, NYHA class II, III or IV.~* Coronary artery or cerebrovascular disease.~* Active foot ulceration.~* Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).~* Active malignancy, except basal cell or squamous cell skin cancers.~* Major surgical operation within 30 days prior to screening.~* Seizure disorder (epilepsy).~* Contraindication to an MRI scan, including having metallic splinters in the eye, a cardiac pacemaker, defibrillator, or any other ferromagnetic or electronically charged implanted device, or ferromagnetic clip(s) in the central nervous system.~* Currently administration of oral or parenteral corticosteroids.~* Use of an investigational drug within 30 days prior to screening.~* Bleeding disorder, treatment with warfarin, or platelet count below 50,000.~* History weight loss of ≥ 5 lbs over the prior month.~* Weight ≥ 300 lbs.~* Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.~* Any reason the principal investigator deems exclusionary.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label Glucagon (Type: EXPERIMENTAL): Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a time since diagnosis of adult-onset Rheumatoid Arthritis (RA) less than 1 year as defined by the 2010 ACR/EULAR classification criteria from Screening Visit~* Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide Antibody (anti-CCP)~* Active RA disease~* DMARD-naïve~* Subject is naïve to RA related biologics~Exclusion Criteria:~* A diagnosis of any other inflammatory Arthritis~* History of infected joint prosthesis, or other significant infection and other serious medical condition~* Known Tuberculosis (TB) disease or high risk of acquiring TB infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol + Methotrexate (Type: EXPERIMENTAL): None
- Placebo + Methotrexate (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with newly diagnosed acromegaly~* age above 18 years~* no previous treatments for acromegaly~Exclusion Criteria:~* primary surgery~* concomitant hyperprolactinemia if requiring combined treatment with dopamine-agonist~* primary treatment with lanreotide~* treatment duration less than 24 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy children 12 months of age at enrollment~Exclusion Criteria:~* Height and weight ratio outside of the 5th to 100th percentile for adjusted age~* Historical and/or biochemical evidence of hepatic, renal, or hematopoetic dysfunction~* Historical or physical evidence of a neurologic disease/condition (excluding simple, febrile seizures)~* Historical or physical evidence of any disorder associated with swallowing and/or gastrointestinal function~* Concomitant therapy with drugs or other products known to alter the activity of hepatic or intestinal microsomal enzymes(e.g., inducers or inhibitors of CYPs 1A2, 2D6, and/or 3A4), P-glycoprotein or potential competing substrates for the CYPs, under study within 7 days of a scheduled phenotyping evaluation~* Evidence of behavioral, developmental, or psychosocial conditions in the subjects and/or parents/caregivers that, in the opinion of the investigator, would have the potential to adversely impact the level of compliance required for successful study completion~* Evidence of geographic instability (i.e., moving of primary residence within last 24 months) that would adversely influence compliance with repeated study visits necessary for completion of the protocol~* Lack of telephone access required to insure adequate subject contact/follow-up~* Inability to obtain written informed consent from the subject's parents/guardians

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete